[Treatment of pyocyanic bacillus superinfections in children with cystic fibrosis using a new cephalosporin: ceftazidime].
D000293:Adolescent; D002442:Ceftazidime / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D003550:Cystic Fibrosis / Q000150:complications* / Q000382:microbiology; D005260:Female; D006801:Humans; D008297:Male; D008826:Microbial Sensitivity Tests; D011552:Pseudomonas Infections / Q000188:drug therapy*; D011550:Pseudomonas aeruginosa / Q000187:drug effects / Q000302:isolation & purification; D014581:Urticaria / Q000139:chemically induced
D002442:Ceftazidime
Traitement des surinfections à bacille pyocyanique d'enfants mucoviscidosiques par une nouvelle céphalosporine: la ceftazidime.